



Combat Drugs Limited

Regd. Off: 4th Floor, Plot No. 94,
Sagar Society, Road No.2,
Banjara Hills, Hyderabad – 500 034
D.L.No.TG/15/04/2016-14766 /14767

Works: 9-109/9, Plot No.112,
Road No. 14, Gayatri Nagar,
Bouduppal, Hyd - 500039, T.S
CIN No.L24230TG1986PLC006781

Ph: (+91)-40-48536100
Url: www.combatdrugs.in
Email: info@combatdrugs.in
GST:36AAACC8372L1ZB

14/11/2018

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting – Quarterly Results

Dear Sir,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and all other applicable provisions and with reference to our letter dated 6th November, 2018, this is to inform you that the meeting of the Board of Directors of the company was held today ie; 14th November, 2018 at 5.00 P.M and concluded at 6.00 P.M., wherein the Board of directors of the company approved the Un-Audited Financial Results (Stand Alone and Consolidated) for the quarter and Half Year Ended 30th September, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- 1) Statement of UnAudited Financial Results (Standalone and Consolidated) for the quarter and Half Year Ended 30th September, 2018.
- 2) Auditors Report on Financial Results (Standalone and Consolidated).

Please Note that the opinion given by the Statutory Auditor in the Enclosed Audit Report is unmodified opinion.

We kindly request you to take the same on record and oblige.

Your Sincerely,
For **COMBAT DRUGS LIMITED**

SUSHANT MOHAN LAL
(DIRECTOR & COMPLIANCE OFFICER)



COMBAT DRUGS LIMITED
(CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society
Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034
URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100
Standalone Financial Results For the Quarter and Half Year Ended 30th September, 2018

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Half Year ended		Year Ended
	30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	31.03.2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	133.30	485.60	22.44	618.90	26.03	101.63
II. Other income	0.62	-	0.46	0.62	0.46	11.37
III.Total revenue (I + II)	133.92	485.60	22.90	619.52	26.49	113.00
IV. Expenses						
Cost of materials consumed	120.00	480.32	-	600.32	0.80	43.42
Changes in inventories of finished goods and stock in trade	(12.58)	(9.75)	-	(22.33)	-	(2.70)
Employee benefits expense	4.50	4.35	7.20	8.85	13.05	24.94
Other expenses	10.65	3.27	3.37	13.92	8.09	29.10
Total expenses	122.56	478.19	10.57	600.76	21.94	94.76
V. Profit/(Loss) before tax (III - IV)	11.35	7.41	12.33	18.76	4.55	18.24
VI. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	-	-	-	-	-	-
VII. Profit/(Loss) for the period (V-VI)	11.35	7.41	12.33	18.76	4.55	18.24
VIII. Other comprehensive income	-	-	-	-	-	-
IX. Total comprehensive income for the year	11.35	7.41	12.33	18.76	4.55	18.24
Paid Up Equity Share Capital (FV of Rs 10 each)	800.00	800.00	800.00	800.00	800.00	800.00
X. Earning per equity						
(1) Basic	0.14	0.09	0.15	0.23	0.06	0.23
(2) Diluted	0.14	0.09	0.15	0.23	0.06	0.23

Notes

- 1) The above results for the quarter and six months ended 30 September 2018 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 14th November 2018.
- 2) According to the requirements of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, revenue for the quarter ended 30 June 2017 was reported inclusive of excise duty. Consequent to the introduction of Goods and Service Tax ("GST") with effect from 1 July 2017 which replaces excise duty and other input taxes, the revenue for the quarter and six months ended 30 September 2018, 30 June 2018 & 31 March 2018 and year ended 31 March 2018 is reported net of GST.
- 3) The Company has only one operating segment as per the requirements of Ind AS 108 "Operating Segments".
- 4) The statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
- 5) Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on Behalf of the Board

Sushant Mohan Lal
Director

Place: Hyderabad
Date : 14.11.2018

COMBAT DRUGS LIMITED

(CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society

Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Standalone Statement of Assets and Liabilities

Particulars	30.09.2018	31.03.2018
	Unaudited	Audited
I. ASSETS		
Non-current Assets		
(a) Financial assets		
(i) Investments	4.56	0.05
(b) Other non-current assets	0.30	0.30
Current Assets		
(a) Inventories	32.05	9.73
(b) Financial assets		
(i) Trade receivables	640.94	58.78
(ii) Cash and cash equivalents	4.26	2.29
(c) Other current assets	222.97	225.05
TOTAL ASSETS	905.09	296.20
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	800.00	800.00
(b) Other equity	(569.22)	(587.98)
Liabilities		
Non-Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	-	-
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	11.26	13.30
(ii) Trade payables		
-total outstanding dues of micro enterprises and small enterprises	-	-
-total outstanding dues of creditors other than micro enterprises and small enterprises	644.63	55.89
(iii) Other Financial liabilities	17.53	14.42
(b) Other current liabilities	0.90	0.57
TOTAL EQUITY AND LIABILITIES	905.09	296.20



For and on Behalf of the Board

Sushant Mohan Lal
DirectorPlace: Hyderabad
Date : 14.11.2018

COMBAT DRUGS LIMITED (CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society, Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Consolidated Financial Results For the Quarter and Half Year Ended 30th September, 2018

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended		Half Year ended	Year Ended
	30.09.2018	30.06.2018	30.09.2018	31.03.2018
	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	133.32	486.26	619.58	50.42
II. Other income	0.62	-	0.62	62.58
III.Total revenue (I + II)	133.94	486.26	620.20	113.00
IV. Expenses				
Cost of materials consumed	120.00	480.32	600.32	43.42
Changes in inventories of finished goods and stock in trade	(12.58)	(9.75)	(22.33)	(2.70)
Employee benefits expense	4.50	4.35	8.85	24.94
Other expenses	12.91	3.51	16.41	29.10
Total expenses	124.82	478.42	603.25	94.76
V. Profit/(Loss) before tax (III - IV)	9.12	7.84	16.95	18.24
VI. Tax expense:				
(1) Current tax	-	-	-	-
(2) Deferred tax	-	-	-	-
VII. Profit/(Loss) for the period (V-VI)	9.12	7.84	16.95	18.24
VIII. Other comprehensive income				
Items that will be reclassified to profit or loss:				
i) Exchange differences	-	-	(0.05)	-
IX. Total comprehensive income for the year	9.12	7.84	16.90	18.24
Total comprehensive income attributable to				
Owners of the parent	9.12	7.84	16.90	18.24
Non controlling Interests	-	-	-	-
Paid Up Equity Share Capital (FV of Rs 10 each)	800.00	800.00	800.00	800.00
X. Earning per equity				
(1) Basic	0.11	0.10	0.21	0.23
(2) Diluted	0.11	0.10	0.21	0.23

Notes

- The above results for the quarter and six months ended 30 September 2018 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at the meeting held on 14th November 2018.
- According to the requirements of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, revenue for the quarter ended 30 June 2017 was reported inclusive of excise duty. Consequent to the introduction of Goods and Service Tax ("GST") with effect from 1 July 2017 which replaces excise duty and other input taxes, the revenue for the quarter and six months ended 30 September 2018, 30 June 2018 & 31 March 2018 and year ended 31 March 2018 is reported net of GST.
- The above results include results of wholly owned subsidiaries
-RA Labs Pte Ltd, Singapore and - ICP Solutions Private Limited, India
- The Group has only one reportable segment as per the requirements of Ind AS 108 "Operating Segments".
- The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".
- The statement is as per Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.
- Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.
- Figures for Half year and Quarter ended 30.09.2017 are not presented as Consolidation is applicable from third quarter of FY 2017-18.



For and on Behalf of the Board

Sushant Mohan Lal
DirectorPlace: Hyderabad
Date : 14.11.2018

COMBAT DRUGS LIMITED

(CIN CL23230TG1986PLC006781)

Regd.off: 4th Floor , Plot No.94,Sagar society

Banjarahills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, Mail: info@combatdrugs.in, Ph: 040-48536100

Consolidated Statement of Assets and Liabilities

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	30.09.2018	31.03.2018
	Unaudited	Audited
I. ASSETS		
Non-current Assets		
(a) Other non-current assets	0.30	0.30
Current Assets		
(a) Inventories	32.05	9.73
(b) Financial assets		
(i) Trade receivables	640.94	58.78
(ii) Cash and cash equivalents	5.15	2.29
(c) Other current assets	224.99	225.10
TOTAL ASSETS	903.43	296.20
II. EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	800.00	800.00
(b) Other equity	(570.89)	(587.98)
Liabilities		
Current Liabilities		
(a) Financial liabilities		
(i) Borrowings	11.26	13.30
(ii) Trade payables		
-total outstanding dues of micro enterprises and small enterprises	-	-
-total outstanding dues of creditors other than micro enterprises and small enterprises	644.63	55.89
(iii) Other Financial liabilities	17.53	14.42
(b) Other current liabilities	0.90	0.57
TOTAL EQUITY AND LIABILITIES	903.43	296.20



For and on Behalf of the Board

Sushant Mohan Lal
DirectorPlace: Hyderabad
Date: 14.11.2018

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM FINANCIAL STATEMENTS**


To
The Board of Directors of Combat Drugs Limited

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Combat Drugs Limited** ("the Company"), for the quarter and half year ended 30th September, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by the Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information* performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.0001258)


A.V.Sadasiva
Partner
M.No:018404



Place: Secunderabad
Date: 14.11.2018

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF
INTERIM FINANCIAL STATEMENTS**

To

The Board of Directors of Combat Drugs Limited

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Combat Drugs Limited ("Holding Company") and its wholly owned subsidiaries ICP Solutions Private Limited and RA Labs PTE Ltd, Singapore together referred to as "the Group"), for the quarter and half year ended 30th September, 2018 ("the Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.

This Statement which is the responsibility of the Holding Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes interim financial results and other financial information, in respect of wholly owned subsidiaries whose interim financial results / information reflects total assets of Rs.3.12 Lakhs as at September 30, 2018 and total revenues of Rs.(2.23 Lakhs) and Rs.(1.82 Lakhs) for the quarter ended and period ended on that date.



Such financial information has been prepared in accordance with accounting principles generally accepted in its country and which has not been audited and which is certified by the Management. The Management has converted the financial statements of these subsidiaries from accounting principles generally accepted in its country to accounting principles generally accepted in India. In our opinion and according to the information and explanations given to us by the Management, these financial results and other financial information are not material to the Group. Our opinion is not modified in respect of this matter.

Based on our review conducted as above and based on the consideration of the report of other auditor referred in paragraph above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Secunderabad
Date: 14.11.2018

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)


A.V.Sadasiva

Partner
M.No:018404

